Lifecore Historical Income Statement

LFCR Stock

7.46 0.15 2.05%

Historical analysis of Lifecore Biomedical income statement accounts such as Gross Profit of 50.2 M can show how well Lifecore Biomedical performed in making a profits. Evaluating Lifecore Biomedical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lifecore Biomedical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Lifecore Biomedical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lifecore Biomedical is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

About Lifecore Income Statement Analysis

Lifecore Biomedical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lifecore Biomedical shareholders. The income statement also shows Lifecore investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Lifecore Biomedical Income Statement Chart

At this time, Lifecore Biomedical's Interest Income is relatively stable compared to the past year. As of 11/26/2024, Net Income From Continuing Ops is likely to grow to about 9.8 M, while Total Revenue is likely to drop slightly above 121.8 M.

Gross Profit Other Operating Expenses Research Development Income Tax Expense Net Income From Continuing Ops

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Lifecore Biomedical minus its cost of goods sold. It is profit before Lifecore Biomedical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lifecore Biomedical. It is also known as Lifecore Biomedical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Lifecore Biomedical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Interest Income is relatively stable compared to the past year. As of 11/26/2024, Net Income From Continuing Ops is likely to grow to about 9.8 M, while Total Revenue is likely to drop slightly above 121.8 M.

	2021	2023	2024 (projected)
Total Revenue	185.8M	128.3M	121.8M
Interest Expense	17.4M	18.1M	19.0M

Total Revenue Interest Expense

Lifecore Biomedical income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Selling And Marketing Expenses	Tax Provision	Net Interest Income	Interest Income	Discontinued Operations	Net Income From Continuing Ops	Reconciled Depreciation
Depreciation And Amortization		0.11	0.1	0.33	0.09	0.02	-0.41	0.25	-0.22	0.07	0.23	0.06	0.06	-0.16	0.08	-0.02	0.31	0.31	-0.09	0.0	-0.21	0.02	-0.05
Interest Expense	0.11		-0.47	-0.13	-0.44	-0.27	-0.56	-0.02	-0.57	-0.5	0.2	-0.59	-0.44	-0.56	-0.42	0.32	-0.65	-0.45	-0.99	-0.96	-0.94	-0.53	-0.17
Total Revenue	0.1	-0.47		0.89	1.0	0.01	0.4	0.62	0.44	1.0	0.7	0.1	-0.02	0.19	-0.03	0.48	0.56	-0.18	0.54	0.39	0.52	0.08	0.5
Gross Profit	0.33	-0.13	0.89		0.9	0.02	0.21	0.77	0.3	0.87	0.86	0.0	-0.07	0.08	-0.12	0.61	0.42	-0.21	0.2	0.1	0.2	-0.05	0.38
Other Operating Expenses	0.09	-0.44	1.0	0.9		-0.02	0.37	0.63	0.42	1.0	0.73	0.07	-0.05	0.17	-0.06	0.51	0.55	-0.22	0.52	0.37	0.49	0.06	0.51
Operating Income	0.02	-0.27	0.01	0.02	-0.02		0.44	0.05	0.48	0.01	-0.31	0.72	0.66	0.57	0.74	-0.48	0.01	0.44	0.2	0.27	0.25	0.33	-0.33
Ebit	-0.41	-0.56	0.4	0.21	0.37	0.44		0.09	0.98	0.42	-0.12	0.62	0.65	0.81	0.46	-0.18	0.27	0.41	0.53	0.43	0.76	0.48	-0.18
Research Development	0.25	-0.02	0.62	0.77	0.63	0.05	0.09		0.15	0.59	0.78	-0.02	0.04	0.09	-0.27	0.54	0.07	-0.28	0.09	-0.01	0.1	-0.07	0.24
Ebitda	-0.22	-0.57	0.44	0.3	0.42	0.48	0.98	0.15		0.45	-0.08	0.68	0.71	0.84	0.51	-0.2	0.35	0.51	0.54	0.46	0.76	0.53	-0.2
Cost Of Revenue	0.07	-0.5	1.0	0.87	1.0	0.01	0.42	0.59	0.45		0.68	0.11	-0.01	0.2	-0.02	0.46	0.57	-0.18	0.57	0.42	0.54	0.09	0.51
Total Operating Expenses	0.23	0.2	0.7	0.86	0.73	-0.31	-0.12	0.78	-0.08	0.68		-0.39	-0.36	-0.25	-0.49	0.84	0.18	-0.54	-0.1	-0.23	-0.12	-0.31	0.4
Income Before Tax	0.06	-0.59	0.1	0.0	0.07	0.72	0.62	-0.02	0.68	0.11	-0.39		0.85	0.91	0.8	-0.44	0.33	0.73	0.55	0.61	0.65	0.87	-0.46
Total Other Income Expense Net	0.06	-0.44	-0.02	-0.07	-0.05	0.66	0.65	0.04	0.71	-0.01	-0.36	0.85		0.85	0.68	-0.39	0.2	0.77	0.4	0.44	0.57	0.63	-0.51
Net Income	-0.16	-0.56	0.19	0.08	0.17	0.57	0.81	0.09	0.84	0.2	-0.25	0.91	0.85		0.59	-0.25	0.33	0.65	0.53	0.53	0.73	0.85	-0.48
Income Tax Expense	0.08	-0.42	-0.03	-0.12	-0.06	0.74	0.46	-0.27	0.51	-0.02	-0.49	0.8	0.68	0.59		-0.57	0.15	0.63	0.38	0.45	0.42	0.55	-0.34
Selling General Administrative	-0.02	0.32	0.48	0.61	0.51	-0.48	-0.18	0.54	-0.2	0.46	0.84	-0.44	-0.39	-0.25	-0.57		0.06	-0.64	-0.21	-0.33	-0.17	-0.23	0.41
Selling And Marketing Expenses	0.31	-0.65	0.56	0.42	0.55	0.01	0.27	0.07	0.35	0.57	0.18	0.33	0.2	0.33	0.15	0.06		0.45	0.65	0.67	0.61	0.39	0.03
Tax Provision	0.31	-0.45	-0.18	-0.21	-0.22	0.44	0.41	-0.28	0.51	-0.18	-0.54	0.73	0.77	0.65	0.63	-0.64	0.45		0.38	0.53	0.47	0.61	-0.63
Net Interest Income	-0.09	-0.99	0.54	0.2	0.52	0.2	0.53	0.09	0.54	0.57	-0.1	0.55	0.4	0.53	0.38	-0.21	0.65	0.38		0.96	0.94	0.51	0.22
Interest Income	0.0	-0.96	0.39	0.1	0.37	0.27	0.43	-0.01	0.46	0.42	-0.23	0.61	0.44	0.53	0.45	-0.33	0.67	0.53	0.96		0.87	0.55	0.07
Discontinued Operations	-0.21	-0.94	0.52	0.2	0.49	0.25	0.76	0.1	0.76	0.54	-0.12	0.65	0.57	0.73	0.42	-0.17	0.61	0.47	0.94	0.87		0.62	0.05
Net Income From Continuing Ops	0.02	-0.53	0.08	-0.05	0.06	0.33	0.48	-0.07	0.53	0.09	-0.31	0.87	0.63	0.85	0.55	-0.23	0.39	0.61	0.51	0.55	0.62		-0.43
Reconciled Depreciation	-0.05	-0.17	0.5	0.38	0.51	-0.33	-0.18	0.24	-0.2	0.51	0.4	-0.46	-0.51	-0.48	-0.34	0.41	0.03	-0.63	0.22	0.07	0.05	-0.43

Click cells to compare fundamentals

Lifecore Biomedical Account Relationship Matchups

Lifecore Biomedical income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	(4.3M)	8.6M	17.9M	7.1M	8M	6.4M
Interest Expense	9.6M	15.3M	17.4M	17.3M	18.1M	19.0M
Total Revenue	557.6M	590.4M	544.2M	185.8M	128.3M	121.8M
Gross Profit	75.0M	81.5M	50.4M	50.6M	41.9M	50.2M
Other Operating Expenses	598.7M	538.3M	189.4M	185.7M	135.4M	128.7M
Operating Income	(8.3M)	(6.9M)	(3.6M)	3.5M	9.3M	5.7M
Ebit	(8.3M)	4.4M	(85.9M)	(5.1M)	(7.2M)	(6.8M)
Research Development	11.5M	11.1M	10.2M	7.8M	8.6M	7.4M
Ebitda	(12.6M)	13.0M	(68.0M)	2.0M	812K	771.4K
Cost Of Revenue	515.4M	462.7M	135.4M	135.2M	86.4M	82.1M
Total Operating Expenses	83.3M	75.6M	54.0M	50.5M	49.0M	42.6M
Income Before Tax	(51.3M)	(40.5M)	(52.1M)	(51.9M)	9.5M	10.0M
Total Other Income Expense Net	(43.0M)	(21.0M)	(48.5M)	(8.9M)	183K	192.2K
Net Income	(38.2M)	(32.7M)	(97.4M)	(46.1M)	12.0M	12.6M
Income Tax Expense	1.5M	(13.1M)	(7.8M)	(5.8M)	183K	173.9K
Selling General Administrative	72.1M	65.3M	46.1M	42.4M	43.0M	57.3M
Selling And Marketing Expenses	1.4M	1.3M	100K	200K	5.1K	4.8K
Tax Provision	(13.1M)	(7.8M)	(5.8M)	301K	183K	192.2K
Net Interest Income	(9.5M)	(15.3M)	(17.3M)	(18.1M)	(18.1M)	(19.0M)
Interest Income	103K	48K	81K	68K	61.2K	71.2K
Discontinued Operations	(16.3M)	(23.1M)	(51.2M)	(33.2M)	(29.9M)	(31.4M)
Net Income From Continuing Ops	(38.2M)	(32.7M)	(46.3M)	(69.0M)	9.3M	9.8M
Reconciled Depreciation	18.8M	19.9M	17.9M	13.5M	8.9M	12.6M
Net Income Applicable To Common Shares	(38.2M)	(32.7M)	(97.4M)	(102.2M)	(92.0M)	(87.4M)

Pair Trading with Lifecore Biomedical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.

Moving against Lifecore Stock

0.8	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.79	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.79	TCHH	Trustcash Holdings	Pair Corr
0.78	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.76	AGL	agilon health Buyout Trend	Pair Corr

The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.

The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lifecore Historical Income Statement

About Lifecore Income Statement Analysis

Lifecore Biomedical Income Statement Chart

Gross Profit

Other Operating Expenses

Lifecore Biomedical income statement Correlations

Lifecore Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lifecore Biomedical income statement Accounts

Pair Trading with Lifecore Biomedical

Moving against Lifecore Stock

Additional Tools for Lifecore Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Other Operating Expenses
Ebitda	+ 0.98	Ebit
Interest Income	+ 0.96	Net Interest Income
Discontinued Operations	+ 0.94	Net Interest Income

Net Interest Income	- 0.99	Interest Expense
Interest Income	- 0.96	Interest Expense
Discontinued Operations	- 0.94	Interest Expense
Selling And Marketing Expenses	- 0.65	Interest Expense
Tax Provision	- 0.64	Selling General Administrative
Reconciled Depreciation	- 0.63	Tax Provision